FDA testosterone label changes, 2026: what actually changed

Testosterone products have gone through two distinct rounds of FDA labeling action in the past year and a half, and conflating them is the easiest way to misread the news. The first, finalized in February 2025, changed what the label says about cardiovascular and blood-pressure risk, based on a large dedicated safety trial.^[1] The second, announced by HHS and FDA in June 2026, is a request to revise language about age-related hypogonadism and to narrow the prostate cancer and BPH warnings.^{[2] [3]} They are not the same kind of change, and treating a disclaimer removal as equivalent to a new approval is exactly the gap this article is written to close.

For the deeper trial-by-trial breakdown of what testosterone therapy does for symptoms, and who a clinical guideline says should avoid it, see our companion article, Testosterone therapy: what the evidence actually shows. This piece focuses specifically on the regulatory label changes themselves and what they do and do not establish.

The 2025 change was driven by TRAVERSE, a large randomized, placebo-controlled trial in more than 5,200 men with hypogonadism, designed specifically to test whether testosterone therapy raises the risk of serious cardiovascular events.^[4]It found major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in 7.0% of the testosterone group versus 7.3% of the placebo group, meeting the trial’s prespecified noninferiority threshold.^[4] Based on that result, the FDA removed the language in the Boxed Warning describing an increased risk of adverse cardiovascular outcomes from all testosterone product labels.^[1]

The same review cycle added a new requirement, not a removal: labeling on increased blood pressure, based on required postmarket ambulatory blood pressure monitoring (ABPM) studies conducted on two testosterone products administered by different routes.^[1] Products without a blood-pressure warning were required to add one. A more accurate label cuts both ways: less warning where the trial data supported it, more warning where separate studies found a real signal.

In June 2026, HHS and the FDA announced a different kind of request: updating testosterone prescribing information to remove the “Limitation of Use” language stating that safety and effectiveness in men with age-related hypogonadism have not been established.^{[2] [3]} That language was added in 2015, when evidence of benefit for this specific population was limited and cardiovascular questions were unresolved. The agencies cited the intervening TRAVERSE result and a broader review of new and existing data as the basis for revisiting it.^[2]

As of this writing, this is a requested update to manufacturer labeling, following the same pattern HHS used in its own announcement language (“requested updates”), rather than confirmation that printed labels for every approved testosterone product have already changed.^[2]

This distinction matters enough to state plainly. FDA labeling can describe a use as “not established” for two different reasons: because trials tested it and found no benefit, or because adequate trials assessing that specific population and endpoint simply have not been done. Removing that language when the underlying reason was the second case does not convert an absence of evidence into evidence of a benefit.

The best dedicated evidence on symptom benefit, the Testosterone Trials, was conducted in men with confirmed low testosterone and found domain-specific results: a moderate benefit for sexual function, a smaller and inconsistent effect on physical function, and no significant benefit for vitality or fatigue, the symptom most closely tied to how age-related low testosterone is marketed to the public.^[5] None of that changed in 2026. What changed is a sentence about liability and approved-use language, not a new head-to-head trial establishing benefit for otherwise healthy aging men.

The second piece of the 2026 request narrows the prostate cancer contraindication so that it applies specifically to metastatic prostate cancer, rather than any known or suspected prostate cancer.^[2] The stated basis is that available clinical trial and epidemiologic data have not shown a general increase in prostate cancer risk with testosterone therapy.^{[2] [3]}

The agencies themselves flag the limit of that reassurance: prostate cancer can take many years to develop, and trial and postmarket follow-up windows are not long enough to rule out a longer-latency effect with certainty.^[2] The BPH warning revision follows a similar shape: clinical trial data available so far do not show worsening BPH symptoms in men with mild to moderate disease, but the agencies describe evidence for severe BPH as limited.^[2]

None of this changes the practical starting point: a prescribing clinician still needs to confirm a diagnosis (symptoms plus repeatedly low morning testosterone) before treatment makes sense, and ongoing monitoring, including blood pressure, PSA, and blood count, remains part of appropriate care regardless of what a label says.^[5] A looser label is not a substitute for an individualized risk-benefit conversation, particularly for men with any prostate cancer history, since the narrowed contraindication does not amount to a clearance for non-metastatic disease.

If your interest is in whether testosterone therapy will actually help how you feel day to day, the more relevant reading is the trial-by-trial breakdown of symptom outcomes in our companion article on what the evidence actually shows, which covers the domain-specific results these label changes do not alter.

The label changes above do not remove the need to watch for the specific safety signals the underlying trials identified.

The FDA has genuinely updated testosterone labeling twice in eighteen months, and both updates are worth knowing about. The 2025 cardiovascular and blood-pressure changes rest on a large dedicated trial and are the more solid of the two. The 2026 changes mostly remove disclaimers and narrow a contraindication based on reassuring but incomplete data; they are real regulatory news, but they are not new proof that testosterone therapy benefits men with ordinary age-related symptoms, and they do not change the guideline criteria used to diagnose hypogonadism in the first place. See how we grade the strength of evidence across topics in our editorial and evidence standards, and browse the rest of our Hormone & Vitality coverage as it grows.

None of this replaces an individual conversation with a prescribing clinician who knows your symptoms, lab results, and health history, including any prostate cancer history. It reflects what the FDA, HHS, and the pivotal trials actually say: a genuinely updated label, not a new verdict on whether testosterone therapy is right for you.